Biohaven Pharmaceutical Holding Company Stock News

Biohaven Pharmaceuticals (BHVN): Q4 Non-GAAP EPS of -$2.32 misses by $0.39.Revenue of $190.01M (+441.2% Y/Y) beats by $14.47M.

Coinciding with the company’s Q4 2021 results, neurology-focused biotech, Biohaven Pharmaceutical (BHVN) announced a licensing deal with Bristol Myers Squibb (BMY) and an agreement…

NEW HAVEN, Conn., Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results…

Biohaven Pharmaceuticals (NYSE:BHVN) is scheduled to announce Q4 earnings results on Friday, February 25th, before market open.The consensus EPS Estimate is -$1.93 (+28.3% Y/Y) and…

Biohaven Pharmaceutical (BHVN) began enrollment in a phase 2/3 trial of Nurtec ODT (rimegepant) 75 mg in patients with chronic rhinosinusitis ((CRS)) with or without nasal polyps

Pfizer (PFE) and Biohaven Pharmaceutical (BHVN) announced that rimegepant known as NURTEC ODT in the U.S

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN ) and Pfizer Inc (NYSE: PFE ) reported topline results from an Asia-Pacific, Phase 3 trial of rimegepant in adults for the acute treatment of migraine. The study met its co-primary endpoints of freedom from pain and freedom from most bothersome migraine-associated symptom, including either nausea, phonophobia, or photophobia at 2-hours following a single oral dose … Full story available on Benzinga.com

Global Coalition for Adaptive Research ((GCAR)) announced that Troriluzole developed by Biohaven Pharmaceutical (BHVN) would be part of its Phase 2/3 trial, designed to evaluate…

Biohaven Pharmaceutical''s (BHVN) subsidiary along with CD3 and LICR at KU Leuven, have entered into an exclusive global license and research agreement to develop and commercialize

NEW HAVEN, Conn. and LEUVEN, Belgium , Jan. 10, 2022 /PRNewswire/ -- Biohaven Therapeutics Ltd., a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ), along with CD3 and LICR at KU Leuven, announced today that they have entered into an exclusive global license and research agreement to develop and commercialize first-in-class TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders. The TRPM3 antagonist platform was discovered at the Centre for Drug Design and Discovery (CD3) and the Laboratory of Ion Channel Research (LICR) at KU Leuven. BHV-2100 is the lead TRPM3 antagonist from the platform and an orally-bioavailable small molecule TRPM3 antagonist. TRPM3 is a cation channel involved in pain signaling and a novel target for the treatment of pain discovered at KU Leuven''s LICR. Consistent with the role of TRPM3 in pain, data generated at KU Leuven demonstrated that BHV-2100 may reduce pain behaviors in animal models without the detrimental side-effects seen with other pain management approaches and mechanisms.

NEW HAVEN, Conn. , Jan. 6, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the fourth quarter of 2021. Based on preliminary unaudited financial information, the Company reported approximately $190 million in net product revenue from sales of NURTEC ODT in the fourth quarter of 2021 and approximately $462 million in net product revenue for 2021. There were no material changes in channel inventory days over the course of the year. The foregoing information reflects the Company''s estimate with respect to net product revenue for NURTEC ODT based on currently available information, which is preliminary and unaudited, is not a comprehensive statement of the Company''s financial results and is subject to completion of the Company''s financial closing procedures. The Company''s final results, which will be issued upon completion of its closing procedures, may vary from these preliminary estimates.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) CAO George C. Clark sold 1,915 shares of the firms stock in a transaction on Monday, December 20th. The stock was sold at an average price of $123.84, for a total transaction of $237,153.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which []

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) CAO George C. Clark sold 1,915 shares of the stock in a transaction dated Monday, December 20th. The stock was sold at an average price of $123.84, for a total transaction of $237,153.60. The transaction was disclosed in a legal filing with the SEC, which is available through this []

Equities analysts predict that Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) will report earnings per share of ($1.93) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Biohaven Pharmaceuticals earnings. The highest EPS estimate is ($0.45) and the lowest is ($2.88). Biohaven Pharmaceutical posted earnings per share of ($3.62) []